No evidence to support or refute probiotics for patients with non-alcoholic fatty liver disease and/or steatohepatitis

Lirussi F, Mastropasqua E, Orando S, Orlando R

Published Online:

January 21, 2009

Probiotics have been proposed as a treatment option for patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis because of their balancing role on the flora of the gut that may act as a potential source of hepatotoxic oxidative injury. This review did not identify any randomised clinical trials with probiotics in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Even if the results from pilot studies seem promising, randomised clinical trials are necessary to asses the clinical implication of probiotics therapy in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Abstract (click to read)

Background:

Non-alcoholic fatty liver disease comprises a spectrum of diseases ranging from simple steatosis to non-alcoholic steatohepatitis, fibrosis, and cirrhosis. Probiotics have been proposed as a treatment option because of their modulating effect on the gut flora that could influence the gut-liver axis.

Objectives:

To evaluate the beneficial and harmful effects of probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.

Search strategy:

We searched The Cochrane Hepato-Biliary Group Controlled Trials Register (July 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 2, 2006), MEDLINE (1966 to May 2006), and EMBASE (1980 to May 2006). No language restrictions were applied.

Selection criteria:

Randomised clinical trials evaluating probiotic treatment in any dose, duration, and route of administration versus no intervention, placebo, or other interventions in patients with non-alcoholic fatty liver disease. The diagnosis was made by history of minimal or no alcohol intake, imaging techniques showing hepatic steatosis and/or histological evidence of hepatic damage, and by exclusion of other causes of hepatic steatosis.

Data collection and analysis:

We had planned to extract data in duplicate and analyse results by intention-to-treat.

Main results:

No randomised clinical trials were identified. Preliminary data from two pilot non-randomised studies suggest that probiotics may be well tolerated, may improve conventional liver function tests, and may decrease markers of lipid peroxidation.

Authors' conclusions:

The lack of randomised clinical trials makes it impossible to support or refute probiotics for patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

This record should be cited as:

Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD005165. DOI: 10.1002/14651858.CD005165.pub2

Assessed as up to date:

November 13, 2006

Find the research

Get full text at The Cochrane Library

Primary Review Group:

Hepato-Biliary Group

Health topics:

Gastroenterology > Fatty liver > Obesity-related

Complementary & alternative medicine > Gastroenterology > Fatty liver

Cochrane Summaries^beta

Independent high-quality evidence for health care decision making

No evidence to support or refute probiotics for patients with non-alcoholic fatty liver disease and/or steatohepatitis

More like this

Copyright © 2012 - The Cochrane Collaboration